These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32173485)

  • 1. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
    Mohamed MZ; Zenhom NM
    Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
    Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
    Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ameliorating effect of leukotriene receptor antagonist in multi-organ toxicity induced in rat offspring, a possible role for epidermal growth factor.
    Abdelzaher WY; Rofaeil RR; Abdel-Hafez SMN; Atta M; Bahaa El-Deen MA; Ali DM
    Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):183-191. PubMed ID: 33504223
    [No Abstract]   [Full Text] [Related]  

  • 4. Montelukast, a cysteinyl leukotriene receptor antagonist, exerts local antinociception in animal model of pain through the L-arginine/nitric oxide/cyclic GMP/K
    Alizamani E; Ghorbanzadeh B; Naserzadeh R; Mansouri MT
    Int J Neurosci; 2021 Oct; 131(10):1004-1011. PubMed ID: 32408781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
    Said MM; Bosland MC
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of sepsis-induced pancreatic injury by leukotriene receptor antagonism via modulation of oxidative injury, and downregulation of inflammatory markers in experimental rats.
    Hagar HH; Alhazmi SM; Arafah M; Bayoumy NM
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3425-3435. PubMed ID: 37962585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats.
    Al-Amran FG; Hadi NR; Hashim AM
    Eur J Cardiothorac Surg; 2013 Feb; 43(2):421-7. PubMed ID: 22851661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury.
    Erşahin M; Çevik Ö; Akakın D; Şener A; Özbay L; Yegen BC; Şener G
    Prostaglandins Other Lipid Mediat; 2012 Dec; 99(3-4):131-9. PubMed ID: 22986158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist.
    Tuğtepe H; Sener G; Cetinel S; Velioğlu-Oğünç A; Yeğen BC
    Eur J Pharmacol; 2007 Feb; 557(1):69-75. PubMed ID: 17173892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
    Venugopal N; Acharya P; Zarei M; Talahalli RR
    Inflammopharmacology; 2019 Oct; 27(5):923-931. PubMed ID: 31309487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia.
    Gupta S; Singh P; Sharma B
    Curr Hypertens Rev; 2024; 20(1):23-35. PubMed ID: 38192137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Montelukast attenuates interleukin IL-1β-induced oxidative stress and apoptosis in chondrocytes by inhibiting CYSLTR1 (Cysteinyl Leukotriene Receptor 1) and activating KLF2 (Kruppel Like Factor 2).
    Li Z; Wang J; Ma Y
    Bioengineered; 2021 Dec; 12(1):8476-8484. PubMed ID: 34565285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.
    Lai J; Hu M; Wang H; Hu M; Long Y; Miao MX; Li JC; Wang XB; Kong LY; Hong H
    Neuropharmacology; 2014 Apr; 79():707-14. PubMed ID: 24456746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
    Shimbori C; Shiota N; Okunishi H
    Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of leukotriene receptor antagonist, montelukast, against cyclophosphamide-induced placental toxicity via modulation of NLRP3/IL-1β signaling pathway in rats.
    Yehia Abdelzaher W; Abdeltwab Ibrahim S; Abdel-Wakeel Abdel-Gaber S; Rady Fadl R; Amgad Mohamed N; Sedik WF; Mohamed Abdel-Aziz A
    Int Immunopharmacol; 2024 Sep; 139():112700. PubMed ID: 39018685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
    Dey M; Singh RK
    Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cysteinyl leukotriene receptor-1 antagonists in treatment of experimentally induced mammary tumor: does montelukast modulate antitumor and immunosuppressant effects of doxorubicin?
    El-Sisi Ael-D; Sokar SS; Salem TA; Abu Risha SE
    Toxicol Ind Health; 2015 Nov; 31(11):1024-36. PubMed ID: 26499992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats.
    Saad MA; Abdelsalam RM; Kenawy SA; Attia AS
    Neurochem Res; 2015 Jan; 40(1):139-50. PubMed ID: 25403620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies.
    Marschallinger J; Altendorfer B; Rockenstein E; Holztrattner M; Garnweidner-Raith J; Pillichshammer N; Leister I; Hutter-Paier B; Strempfl K; Unger MS; Chishty M; Felder T; Johnson M; Attems J; Masliah E; Aigner L
    Neurotherapeutics; 2020 Jul; 17(3):1061-1074. PubMed ID: 32072462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Induces M2 Macrophage Polarization and Inhibits Murine Aortic Aneurysm Formation.
    Kawai Y; Narita Y; Yamawaki-Ogata A; Usui A; Komori K
    Biomed Res Int; 2019; 2019():9104680. PubMed ID: 31263710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.